Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients

Annals of Hematology

Volumn 90, Issue 1, 2011, Pages 47-52

  Qin, Yazhen ^a   Chen, Shanshan ^a   Jiang, Bin ^a   Jiang, Qian ^a   Jiang, Hao ^a   Li, Jinlan ^a   Li, Lingdi ^a   Lai, Yueyun ^a   Liu, Yanrong ^a   Huang, Xiaojun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

BCR ABL kinase domain point mutations; Chinese; Chronic myeloid leukemia; Imatinib resistant

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MUTANT PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL; CANCER STAGING; CHINESE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DIRECT SEQUENCING; DRUG BINDING SITE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METAPHASE CHROMOSOME; MUTATION RATE; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; POINT MUTATION; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PHOSPHOTRANSFERASES; PIPERAZINES; POINT MUTATION; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; YOUNG ADULT;

EID: 78651340549     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-1039-5     Document Type: Article

References (20)

1. H Kantarjian C Sawyers A Hochhaus F Guilhot C Schiffer C Gambacorti-Passerini, et al. 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 645 652 1:CAS:528:DC%2BD38XhsFOjsr8%3D 10.1056/NEJMoa011573 11870241 (Pubitemid 34815868)
2. S O'Brien F Guilhot RA Larson I Gathmann M Baccarani F Cervantes, et al. 2003 Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia N Engl J Med 348 994 1004 10.1056/NEJMoa022457 12637609 (Pubitemid 36302244)
3. S Branford Z Rudzki A Harper A Grigg K Taylor S Durrant, et al. 2003 Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase Leukemia 17 2401 2409 1:CAS:528:DC%2BD3sXps12itbw%3D 10.1038/sj.leu.2403158 14523461 (Pubitemid 38072578)
4. T Lahaye B Riehm U Berger P Paschka P Muller S Kreil, et al. 2005 Response and resistance in 300 patients with BCR-ABL positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer 103 1659 1669 10.1002/cncr.20922 15747376 (Pubitemid 40490027)
5. CL Sawyers A Hochhaus E Feldman JM Goldman CB Miller OG Ottmann, et al. 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase 2 study Blood 99 3530 3539 1:CAS:528:DC%2BD38XjvVGns78%3D 10.1182/blood.V99.10.3530 11986204 (Pubitemid 34534519)
6. A Sureda M Carrasco M de Miguel JA Martinez E Conde MA Sanz, et al. 2003 Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia Haematologica 88 1213 1220 1:CAS:528:DC%2BD2cXkslKmug%3D%3D 14607749
7. NP Shah JM Nicoll B Nagar ME Gorre RL Paquette J Kuriyan, et al. 2002 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 117 125 1:CAS:528:DC%2BD38XmslSks7c%3D 10.1016/S1535-6108(02)00096-X 12204532 (Pubitemid 41039112)
8. ME Gorre M Mohammed K Ellwood N Hsu R Paquette PN Rao, et al. 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 876 880 1:CAS:528:DC%2BD3MXlvVKrsbs%3D 10.1126/science.1062538 11423618 (Pubitemid 32743979)
9. JV Melo C Chuah 2007 Resistance to imatinib in chronic myeloid leukaemia Cancer Lett 249 121 132 1:CAS:528:DC%2BD2sXjsVektLs%3D 10.1016/j.canlet.2006.07. 010 16949736 (Pubitemid 46452920)
10. Branford S (2007) Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 376-383
11. SH Kim D Kim DW Kim HG Goh SE Jang J Lee, et al. 2009 Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent Hematol Oncol 27 190 197 1:CAS:528:DC%2BC3cXhtVSku7o%3D 10.1002/hon.894 19274615
12. J Apperley 2007 Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 1018 1029 1:CAS:528:DC%2BD2sXht1GrsbjL 10.1016/S1470-2045(07)70342-X 17976612 (Pubitemid 47629897)
13. S Soverini S Colarossi A Gnani G Rosti F Castagnetti A Poerio, et al. 2006 Contribution of abl kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia Clin Cancer Res 12 7374 7379 1:CAS:528: DC%2BD28XhtlCrtr%2FK 10.1158/1078-0432.CCR-06-1516 17189410 (Pubitemid 46095411)
14. Y Qin B Jiang Q Jiang H Jiang J Li Y Zhang, et al. 2009 Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up Ann Hematol 88 37 41 1:CAS:528:DC%2BD1cXhsVWhs7bF 10.1007/s00277-008- 0548-y 18651143
15. T Ernst P Erben MC Müller P Paschka T Schenk J Hoffmann, et al. 2006 Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib Haematologica 93 186 192 10.3324/haematol.11993
16. A Hochhaus S Kreil AS Corbin P La Rosee MC Muller T Lahaye, et al. 2002 Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy Leukemia 16 2190 2196 1:CAS:528:DC%2BD38XotFWktrk%3D 10.1038/sj.leu.2402741 12399961 (Pubitemid 35331833)
17. S Branford Z Rudzki I Parkinson A Grigg K Taylor JF Seymour, et al. 2004 Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations Blood 104 2926 2932 1:CAS:528:DC%2BD2cXpslKjurc%3D 10.1182/blood-2004-03-1134 15256429 (Pubitemid 39434981)
18. M Azam RR Latek GQ Daley 2003 Mechanisms of autoinhibition and STI571/imatinib resistance revealed by mutagenesis of BCR-ABL Cell 112 831 843 1:CAS:528:DC%2BD3sXivVWjsbY%3D 10.1016/S0092-8674(03)00190-9 12654249 (Pubitemid 36378885)
19. M Deininger E Buchdunger BJ Druker 2005 The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 105 2640 2653 1:CAS:528:DC%2BD2MXivFGmsb0%3D 10.1182/blood-2004-08-3097 15618470 (Pubitemid 40446252)
20. N Sorel L Roy G Martineau F Guilhot AG Turhan JC Chomel 2006 Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML Blood 108 1782 1783 1:CAS:528:DC%2BD28Xpt1Sksrw%3D 10.1182/blood-2006-03-011668 16926302 (Pubitemid 44316159)